VolitionRx Limited announced the signing of a global supply agreement with a market leader in pet healthcare. Through Volition's supply agreement, the Company is engaged as a worldwide provider of the Nu.Q® Vet Cancer Test through its reference laboratory network for cancer indications in animal health. There are approximately 84 million pet dogs in the United States and just under 50% of dogs will have at least one veterinary care visit per annum which Volition believes will provide an incredible opportunity to screen those senior dogs (over 7 years) and breeds at risk of cancer from 4 years and upwards.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.708 USD | +4.89% |
|
+4.13% | -1.26% |
May. 14 | Transcript : VolitionRx Limited, Q1 2024 Earnings Call, May 14, 2024 | |
May. 13 | VolitionRx Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.26% | 58.64M | |
+11.68% | 3.7B | |
+0.37% | 2.28B | |
-21.21% | 1.99B | |
-23.77% | 1.6B | |
+14.81% | 999M | |
+18.25% | 739M | |
-10.04% | 685M | |
-36.12% | 461M | |
-4.47% | 279M |
- Stock Market
- Equities
- VNRX Stock
- News VolitionRx Limited
- VolitionRx Limited Signs Global Supply Agreement for Nu.Q® Vet Cancer Test